| Name | Title | Contact Details |
|---|---|---|
Edward Berg |
Vice President and Deputy General Counsel | Profile |
Edward Berg |
Vice President and Deputy General Counsel | Profile |
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.
Percivia is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Controle Analytique Inc is a Thetford Mines, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. The company has subsidiaries in China and in the USA.
Delivering on our promise to identify any microbe, from any sample, anywhere in the world will take a team of dedicated, passionate, and experienced individuals. The members of our team at IDbyDNA have a strong track record of building successful organizations and bring a breadth of multi-disciplinary experience including; microbial genomics, bioinformatics, software engineering, laboratory medicine, and commercialization. In concert with the global community of researchers, clinicians, industry partners and policy makers, we will revolutionize microbial detection and bring new solutions to solve problems that are not currently addressable with today`s technologies.